Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across more than 165 countries and territories [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter issued by the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million [5]. - Following this announcement, Viatris's stock price fell about 15%, dropping from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=148432&from=4CLASS PERIOD: August 8, 2024 to February ...

Group 1 - The company has undergone significant integration since the merger of Mylan and Upjohn, focusing on streamlining operations and divesting non-core assets [4][5] - The strategic direction for the next 3 to 5 years emphasizes moving up the value chain towards more durable high-growth brands [3] - Recent divestments include biosimilars, OTC products, women's health, and active pharmaceutical ingredients (API) [4] Group 2 - The company is committed to executing its strategy by leveraging a diverse base of business assets [5]

Core Viewpoint - Viatris Inc. is facing a securities class action lawsuit due to allegations of failing to disclose material information during the specified class period, leading to significant investor losses [4]. Group 1: Lawsuit Details - Investors who incurred losses exceeding $100,000 from purchasing Viatris securities between August 8, 2024, and February 26, 2025, have until June 3, 2025, to file lead plaintiff applications [1]. - The lawsuit is pending in the United States District Court for the Western District of Pennsylvania, with the case titled Quinn v. Viatris Inc., et al., No. 25-cv-466 [5]. - Viatris announced disappointing fiscal 2025 guidance on February 27, 2025, attributing the decline to issues related to the Indore facility, which caused the stock price to drop from $11.24 to $9.53 per share [5]. Group 2: Legal Representation - Kahn Swick & Foti, LLC (KSF) is representing investors in this class action, and they are recognized as one of the top boutique securities litigation law firms in the nation [6]. - Investors may choose to serve as lead plaintiffs, allowing them to select lead counsel, direct litigation, and participate in settlement discussions [2]. Group 3: Company Background - Viatris is a publicly traded company that has faced scrutiny for its disclosure practices, which are now under legal examination due to the recent allegations [4]. - KSF has a history of serving various clients, including institutional and retail investors, in recovering losses from corporate fraud or malfeasance [6].

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission- ...

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=147747&from=3 CLASS PERIOD: August 8, 2024 to F ...

Core Viewpoint - Viatris Inc. has faced significant stock price decline following disappointing financial results and lower-than-expected guidance for 2025, prompting investigations into potential claims against the company [4]. Group 1: Financial Performance - On February 27, 2025, Viatris reported its fourth quarter and full year 2024 financial results, which missed consensus estimates for key metrics [4]. - The company provided lower-than-expected full-year guidance for 2025, indicating potential ongoing challenges [4]. Group 2: Stock Market Reaction - Following the announcement of the financial results and guidance, Viatris's stock price fell by $1.71 per share, or 15.21%, closing at $9.53 per share on February 27, 2025 [4]. Group 3: Regulatory Issues - Viatris updated on remediation efforts at a manufacturing facility in India after receiving a warning letter and import alert from the U.S. Food and Drug Administration, stating that it is "more than halfway through its remediation efforts" and expects completion in a few months [4].

SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give u ...

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, captioned Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company supplying medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented its facilities as being in "good operating condition" and committed to high-quality manufacturing standards, despite a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection significantly impacted Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results, Viatris disclosed that the negative impact from the Indore facility's inspection would lower 2025 revenue by approximately $500 million and earnings from operations by about $385 million [5]. - Following this announcement, Viatris's stock price dropped roughly 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

NEW YORK, May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2? ...